A+ A A-

25% don’t complete recommended breast cancer treatment

Side effects cited as patients’ most common reason for skipping hormone-blocking therapy or stopping early

ANN ARBOR, Mich. — One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.

Continue reading...